FDA approves high-dose Wegovy 7.2mg for obesity
Key Questions
When did the FDA approve high-dose Wegovy?
The FDA approved the 7.2mg high-dose Wegovy for obesity on March 19. Nationwide rollout began in April across 70,000 pharmacies.
What weight loss results does high-dose Wegovy achieve?
High-dose Wegovy delivers 18.8-21% weight loss. It positions competitively against oral options, Lilly, and generics.
What is the pricing for high-dose Wegovy?
It is priced at $399 cash pay or $25 with insurance. This undercuts competitors like Lilly by about 40%.
Where is high-dose Wegovy available?
Available nationwide in the US at 70,000 pharmacies starting April launch. This expands access for obesity treatment.
How does high-dose Wegovy impact Novo Nordisk's market position?
The launch resets valuation debates, with retail viewing the stock as undervalued. It strengthens Novo's obesity drug portfolio.
Nationwide launch confirmed Apr/May post-Mar19 FDA (7.2mg sema, STEP UP trial 20.7% WL vs 2.4mg 17.5%; $399 cash/$25 ins 70k pharmacies); expands options for stubborn cases, undercuts Lilly Zepbound ~40% WL vs oral/LLY/generics.